ICU Medical Inc. (ICUI) 12-Month Stock Forecast & Price Target Cone

$168.65 +1.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $168.74

ICU Medical Inc. (ICUI) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $4.22B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $168.73 (+0.05%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 4.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+
Cash (9)Whales (9)SEC (15)Macro (12)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE-1.4% Base Target
$202 Bull$166 Base$130 Bear
📬 FREE ICUI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICUI)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY ICUI SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (22% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$160.32+1.7% Next Q
Q2 (-2Q)
50
Grade C-$162.99+2.2% Next Q
Q3 (-1Q)
52
Grade C-$166.62+1.2% Next Q
Current
55
Grade D+$168.65-0.5% Hist 90D α
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICUI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ICUI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.68% YoY Shares) — any gross margin slip below 34.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($164.22) or 200D SMA ($148.59) invalidates the momentum regime and cuts Target Base ($166.37) toward Bear Floor ($129.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICUI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ICUI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ICUI Position Size: $10,000

Shares at $168.65: 59.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $129.77
$7,695
$-2,305 (-23.1%)
12M Consensus BaseTarget $166.37
$9,865
$-135 (-1.4%)
12M Bull Case BreakoutTarget $202.49
$12,007
+$2,007 (+20.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 6
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$17374%A
Goldman SachsSector Coverage LeadUNDERPERFORM$19069%B
JP MorganUS Large-Cap ResearchSELL$14858%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICUI)

  • ✓Walkthrough of ICUI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ICUI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.48%▲ ASCENDING CHANNEL
2026-10-30O $169.6H $170.0L $163.2C $168.7VOL 216.6K
RES: $225.8SUP: $158.1SMA50: $164.2SMA200: $148.6
$198.3$175.7$153.0$130.4$107.8RES $225.8SUP $158.1$168.72026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICUI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
40.6%/yr Implied 5Y Growth

vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICUI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICUI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ICUI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICUI)

Health Care Rank #278 of 1016 ⚔️ IRTC vs ICUI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICUI vs. IRTC, PLSE, NVST, HTFL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ICU Medical Inc. (ICUI) ranks #278 by composite RQD confidence (55/100, grade D+) and #178 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ICUI currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ICUI ACTIVE
ICU Medical Inc.
D+ 55/100 — 36.8% 1.0% +1.36% $4.22B Benchmark Subject
IRTC
iRhythm Holdings Inc.
D 48/100 — 70.6% -13.5% +3.07% $4.21B /irtc-vs-icui →
PLSE
Pulse Biosciences Inc
D- 41/100 — -30.0% -30.7% +3.37% $3.96B /plse-vs-icui →
NVST
Envista Holdings Corporation
D 49/100 84.1x 54.7% 5.1% +2.80% $3.95B /nvst-vs-icui →
HTFL
Heartflow Inc.
D+ 53/100 — 76.8% -12.0% +2.42% $5.26B /htfl-vs-icui →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883984

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICU Medical Inc. (ICUI) reported GAAP revenue of $2.23B (-6.3% vs. FY2024 revenue of $2.38B , and -1.2% cumulative change since FY2023) , GAAP net income of $732.0K, operating cash flow of $179.8M, and free cash flow of $91.8M (-26.4% YoY). On the balance sheet, ICUI closed FY2025 with $4.05B in total assets against $1.27B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.23B $732.0K $179.8M $91.8M $4.05B $1.27B
FY2024 (FY) 2024-12-31 $2.38B -$117.7M $204.0M $124.7M $4.20B $1.53B
FY2023 (FY) 2023-12-31 $2.26B -$29.7M $166.2M $166.2M — —

3. ICUI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ICU Medical Inc. (NASDAQ: ICUI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $168.65 (+1.36% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ICUI ranks #278 in composite RQD confidence.

How does ICUI compare to IRTC and PLSE in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ICUI carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 36.8%, and ROIC of 1.0%. By comparison, IRTC (iRhythm Holdings Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ICUI?

Per ICUI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883984), ICU Medical Inc. generated $2.23B in revenue (-6.3% YoY), $732.0K in net income, and $91.8M in free cash flow against $4.05B in total assets and $1.27B in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ICUI trading relative to its 50-day, 200-day, and 52-week technical levels?

ICUI last traded at $168.65 (+1.36% on volume of 202,523 shares), positioning the stock +2.70% above its 50-day simple moving average ($164.22) and +13.50% above its 200-day simple moving average ($148.59). Across its 52-week range of $113.37 to $192.85, ICUI sits at the 69.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($157.69 to $179.61).

ICUI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ICUI's 12-month stock price target?

ICU Medical Inc. (ICUI) carries a 12-month consensus base price target of $166.37 (-1.4% from $168.65), with a bull-case target of $202.49 and a bear-case floor of $129.77.

Is ICUI stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ICUI D+ (Sell — SELL) with an RQD Confidence score of 55/100.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%